Aripiprazole in the treatment of Alzheimer's disease (original) (raw)

Antidepressant Treatment and Risk of Dementia

Cynthia Lee

The Journal of Clinical Psychiatry, 2016

View PDFchevron_right

Novel Therapeutic Strategies for Alzheimer??S Disease and Related Disorders

Soraya Sajadimajd

Alzheimer Disease & Associated Disorders, 1988

View PDFchevron_right

Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease

Maria Barcikowska

2018

View PDFchevron_right

A comment on “add-on aripiprazole for atypical antipsychotic-induced, clinically significant hyperprolactinemia”

Ahmed Naguy

Indian Journal of Psychological Medicine, 2018

View PDFchevron_right

Use and Safety of Antipsychotics in Behavioral Disorders in Elderly People With Dementia

Giovambattista Sarro

Journal of Clinical Psychopharmacology, 2014

View PDFchevron_right

Reversal of Aripiprazole-Induced Tardive Akathisia by Addition of Pregabalin

Domenico De Berardis

Journal of Neuropsychiatry, 2013

View PDFchevron_right

Clinical practice with anti-dementia drugs: a consensus statement from British Association for

Karl Broich

2006

View PDFchevron_right

Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease

Jari Tiihonen

International Clinical Psychopharmacology, 2015

View PDFchevron_right

Abstracts Second Congress of the European Society for Clinical Neuropharmacology

A. Seghers

Journal of Neural Transmission, 1995

View PDFchevron_right

Drug Therapy for Geriatric Depression

Michael Katz

Drugs & Aging, 1993

View PDFchevron_right

Association between antipsychotics and adverse outcomes in dementia

Ayesha Bangash

Progress in Neurology and Psychiatry, 2017

View PDFchevron_right

Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer’s Disease

Ivana Cacciatore

International Journal of Molecular Sciences, 2016

View PDFchevron_right

An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder

Eric Youngstrom

Journal of Child and Adolescent Psychopharmacology, 2011

View PDFchevron_right

Alzheimer’s disease therapies: Selected advances and future perspectives

Abdelaziz Ghanemi, PhD

Alexandria Journal of Medicine, 2015

View PDFchevron_right

Alzheimer’s disease pathogenesis and therapeutic interventions

Adaeze Echezona, john ogbodo

Journal of Clinical Neuroscience, 2004

View PDFchevron_right

A New Regulatory Road-Map for Alzheimer’s Disease Drug Development

Nigel Greig

Current Alzheimer Research, 2014

View PDFchevron_right

Early diagnosis and treatment of Alzheimer’s disease

Brigitte Guérin

Expert Review of Neurotherapeutics, 2008

View PDFchevron_right

Maraula et al. Neuropharmacol. 2012

Felicita Pedata

View PDFchevron_right

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

Ronald Marcus

The International Journal of Neuropsychopharmacology, 2003

View PDFchevron_right

Pharmacologic Treatment of Agitation and Apathy in Dementia

Shailaja Shah

2007

View PDFchevron_right

Drugs With Anticholinergic Properties, Cognitive Decline, and Dementia in an Elderly General Population

Gian Luigi Gigli

Archives of Internal Medicine, 2009

View PDFchevron_right

Antidepressant use in elderly medical inpatients

Frank Shelp

Journal of General Internal Medicine, 1989

View PDFchevron_right

Evidence of the clinical effectiveness of cognitive pharmaceutical services for aged patients

Fernando Fernandez-Llimos

Age and Ageing, 2013

View PDFchevron_right

Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial

Robert Rosenheck

American Journal of Psychiatry, 2008

View PDFchevron_right

Psychotropic drug use in patients with various chronic somatic diseases

Hugo Smeets

The European Journal of Psychiatry, 2012

View PDFchevron_right